首页 › 基金 › DCVC Opportunity Fund II GP, LLC › RXRX
DCVC Opportunity Fund II GP, LLC 对 RXRX 的持仓历史
RECURSION PHARMACEUTICALS IN · 医疗保健
DCVC Opportunity Fund II GP, LLC 在 Q3 2026 的 13F 申报中披露持有 RXRX(RECURSION PHARMACEUTICALS IN)3,951,141 股,市值约 US$16.3M,约占其申报组合的 88.01%,在其申报持仓中市值排名第 1 位。 DCVC Opportunity Fund II GP, LLC 最近 12 个申报季度中有 12 个季度披露了 RXRX 持仓,最早可追溯至 Q4 2023。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
DCVC Opportunity Fund II GP, LLC 对 RXRX 的持仓演变
DCVC Opportunity Fund II GP, LLC 于 Q4 2023 首次披露 RXRX 持仓:3,951,141 股(约 US$39.0M)。 该持仓在 Q1 2024 达到峰值 3,951,141 股,市值约 US$39.4M。 在 12 次申报中,DCVC Opportunity Fund II GP, LLC 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 3,951,141 股、市值约 US$16.3M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2023 | 3.95M | $38.96M | 新进 |
| Q1 2024 | 3.95M | $39.39M | 持有 |
| Q2 2024 | 3.95M | $29.63M | 持有 |
| Q3 2024 | 3.95M | $26.04M | 持有 |
| Q4 2024 | 3.95M | $26.71M | 持有 |
| Q1 2025 | 3.95M | $20.90M | 持有 |
| Q2 2025 | 3.95M | $19.99M | 持有 |
| Q3 2025 | 3.95M | $19.28M | 持有 |
| Q4 2025 | 3.95M | $16.16M | 持有 |
| Q1 2026 | 3.95M | $12.13M | 持有 |
| Q2 2026 | 3.95M | $14.50M | 持有 |
| Q3 2026 | 3.95M | $16.32M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 RXRX 与 13F 数据
RXRX(RECURSION PHARMACEUTICALS IN)属于医疗保健行业。我们追踪的基金中还有 29 只申报持有 RXRX,申报仓位最大的包括:方舟投资 (US$184.8M), SOFTBANK GROUP CORP. (US$56.3M), MIC Capital Management UK LLP (US$34.1M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 RXRX 的基金
- 方舟投资 44.75M 股 · $184.80M · Q3 2026
- SOFTBANK GROUP CORP. 13.64M 股 · $56.32M · Q3 2026
- MIC Capital Management UK LLP 8.26M 股 · $34.09M · Q3 2026
- Data Collective IV GP, LLC 5.94M 股 · $24.54M · Q3 2026
- GMT CAPITAL CORP 4.86M 股 · $20.06M · Q3 2026
- IQ EQ FUND MANAGEMENT (IRELAND) Ltd 2.68M 股 · $11.06M · Q3 2026
更多关于 DCVC Opportunity Fund II GP, LLC
常见问题
How long has DCVC Opportunity Fund II GP, LLC held RXRX?
DCVC Opportunity Fund II GP, LLC has disclosed RXRX holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is DCVC Opportunity Fund II GP, LLC's current position in RXRX?
As of Q3 2026, DCVC Opportunity Fund II GP, LLC holds 3.95M shares of RXRX (RECURSION PHARMACEUTICALS IN), valued at $16.32M, representing 88.01% of its reported portfolio and ranking #1.
Has DCVC Opportunity Fund II GP, LLC been buying or selling RXRX?
In the latest 13F filing (Q3 2026), DCVC Opportunity Fund II GP, LLC held unchanged its position in RXRX. The position peaked in Q1 2024 at 3.95M shares.
Which other funds hold RXRX?
Other major institutional holders of RXRX include 方舟投资, SOFTBANK GROUP CORP., MIC Capital Management UK LLP, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.